<DOC>
	<DOCNO>NCT01016223</DOCNO>
	<brief_summary>The investigator hypothesize swallow beclomethasone lead improvement symptom decrease number eosinophil esophageal mucosa , also decrease marker tissue inflammation like mast cell , CD4+ T lymphocytes , IL4 , IL-5 , IL13 , GM-CSF TGF-beta well serum ultra-sensitive C-Reactive Protein ( CRP ) . The investigator aim characterize response esophageal inflammation swallow topical glucocorticoid , identify biomarkers assess response treatment . This research elucidate effect treatment beclomethasone various inflammatory marker EoE , currently well-understood . This work explore pathophysiology EoE , potential find non-invasive biomarker high-sensitivity CRP use monitor response treatment .</brief_summary>
	<brief_title>A Randomized Double Blind Placebo Controlled Study Effect Swallowed Beclomethasone Dipropionate Inflammatory Markers Adult Patients With Eosinophilic Esophagitis</brief_title>
	<detailed_description>EoE increasingly recognize clinicopathological diagnosis , characterize marked accumulation eosinophil esophageal mucosa.The presence eosinophils association disease food allergy allergic rhinitis suggest atopic disease . Allergic diseases associate T-helper 2 lymphocyte ( TH2 ) predominant cytokine interleukins 4 , 5 , 13 ( IL4 , IL5 , IL13 ) , know induce IgE synthesis promote eosinophilic infiltration . Granulocyte-Monocyte Colony Stimulating Factor ( GM-CSF ) Transforming Growth Factor ( TGF ) - beta cytokine associate many eosinophilic disorder . Swallowed steroid conventional treatment show improve symptom decrease number eosinophil esophagus patient EoE . However , study investigate effect swallow steroid marker TH2 inflammation adult patient EoE.Currently repeat endoscopic biopsy esophagus tool monitor response treatment . Serum ultra- sensitive CRP non-invasive marker inflammation cardiovascular gastrointestinal disorder . This study propose investigate correlation disease activity potential marker inflammation adult patient EoE previously study . Specific Aim # 1 : To measure baseline level propose panel inflammatory marker : serum ultra-sensitive CRP peripheral eosinophil , well tissue eosinophil , mast cell , CD4 cell , IL-4 , IL-5 , IL-13 , GM-CSF TGF-beta esophagus adult patient eosinophilic esophagitis . Specific Aim # 2 : To determine impact 8 week course treatment swallow beclomethasone level inflammatory marker measure Specific Aim # 1 . Specific Aim # 3 : To determine correlation level propose panel inflammatory marker symptoms EoE 8 week treatment swallow beclomethasone .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male female subject 18 year age old biopsy proven diagnosis EoE . Subjects able willing provide consent repeat EGDs esophageal biopsy , blood work per study protocol . Exclusion criterion : Subjects suspect proven inflammatory bowel disease , malignancy , collagenvascular disease . Subjects used oral , inhaled swallow corticosteroid past 3 month . Subjects pregnant breastfeed Subjects able swallow beclomethasone intolerant medication . Subjects history ischemic heart disease , diabetes dyslipidemia unless stable last six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Eosinophilic esophagitis</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Ultrasensitive CRP</keyword>
</DOC>